Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
Holding DE:BRM?
Track your performance easily
BRM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€36.42 - €58.20
Previous Close€43.01
Volume2.05K
Average Volume (3M)4.69K
Market Cap
€87.03B
Enterprise Value€128.20B
Total Cash (Recent Filing)$6.65B
Total Debt (Recent Filing)$52.39B
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Oct 31, 2024EPS Estimate
€1.42Last Dividend Ex-Date
Jul 05, 2024Dividend Yield4.98%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,027,395,178
10 Day Avg. Volume2,512
30 Day Avg. Volume4,687
Standard Deviation0.07
R-Squared0.04
Alpha0.00635
Financial Highlights & Ratios
Price to Book (P/B)-2.83
Price to Sales (P/S)2.08
Price to Cash Flow (P/CF)10.40
P/FCF Ratio11.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda37.26
Forecast
1Y Price Target
€43.45Price Target Upside1.03% Upside
Rating ConsensusHold
Number of Analyst Covering14
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCendak met both co-primary endpoints for its Ph3 eosinophilic esophagitis (EoE) trial, demonstrating stat-sig reductions in dysphagia days and esophageal eosinophil counts after 24 weeks of treatment.
EarningsBMY reported strong Q2 results and raised 2024 guidance.
Pipeline And Drug DevelopmentReblozyl, Breyanzi, and Sotyktu appear to be building positive momentum for the Growth Portfolio.
Bears Say
Revenue And EarningsBMY's persistent broader challenge is still the same: eroding top-line and EPS post-2026 with lack of visibility on when and where that trend will stop.
Sales GrowthNo sales growth during 2023-30 given heavy patent expiration pressures.
Stock PerformanceAfter a 25% share price rally despite little movement in underlying post-2025 fundamentals, analyst moves to Underweight amidst must-have 2H catalysts, competitor noise/headwinds, and risk of unwind after recent rotation.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.34% Insiders
24.57% Mutual Funds
40.33% Other Institutional Investors
34.76% Public Companies and
Individual Investors
BRM FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €36.42 and its highest was €58.20 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 31, 2024 which is in 67 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Jul 26, 2024. The company reported €1.858 earnings per share for the quarter, beating the consensus estimate of €1.454 by €0.404.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of €0.54 which represents an annual dividend yield of 4.98%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is €1.42.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,027,395,100 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.858 in its last earnings report, beating expectations of €1.454. Following the earnings report the stock price went up 8.335%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 976M.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€43.45 (1.03% Upside)
€43.45 (1.03% Upside)
Blogger Sentiment
Bullish
DE:BRM Sentiment 96%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.98%
12-Months-Change
Fundamentals
Return on Equity
-26.70%
Trailing 12-Months
Asset Growth
1.24%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BRM Company Deck
---
BRM Earnings Call
Q2 2024
0:00 / 0:00
---
BRM Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BRM Stock 12 Month Forecast
Average Price Target
€43.45
▲(1.03% Upside)
Technical Analysis
Best Analysts Covering BRM
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+12.98%
reiterated a sell rating 27 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +12.98% per trade.
---